BCTX - BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients

BriaCell Therapeutics (BCTX) soars 104% premarket after providing an update on the overall survival ((OS)) data in advanced breast cancer patients.These women were treated with BriaCell’s Bria-IMT as monotherapy and also in combination with checkpoint inhibitors, including Merck's Keytruda (pembrolizumab) and Incyte’s retifanlimab.12.0 months average OS benefit was seen in patients receiving combination therapy, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors.In a top responder, OS was 21.4 months plus 100% resolution of ‘eye-bulging’ orbital tumor.OS was of 7.2-9.8 months in similar patients with metastatic breast cancer who have failed 2 prior therapy attempts (third line setting). BriaCell’s immunotherapy treatment appears most effective when the patient’s HLA-type matches with Bria-IMT, allowing BriaCell to potentially identify patients most likely to respond.

For further details see:

BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients